Alnylam Pharma (ALNY) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Alnylam Pharma (ALNY) Tops Q1 EPS by 4c

Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress

May 7, 2015 4:00 PM EDT

Launched Alnylam 2020 Guidance for Advancement and Commercialization of RNAi Therapeutics

Advanced Multiple Clinical Programs and Presented Evidence for Potential Disease-Modifying Activity for Patisiran in Familial Amyloidotic Polyneuropathy (FAP) and ALN-AT3 in Hemophilia

Plans to Present New Clinical Data for ALN-AT3 and Initial Clinical Data for ALN-CC5 in Oral Presentations at Medical Meetings in June

Maintained Strong Balance Sheet with $1.45 Billion in Cash and Expects to End 2015 with Greater than $1.2 Billion in Cash

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More